Wentong Liu1, Yang Yang1, Bincan He1, Fengjun Ma1, Fengzeng Sun1, Min Guo1, Min Zhang1,2, Zhiqiang Dong1,2,3. 1. College of Biomedicine and Health, College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China. 2. Hubei Cancer Hospital, Wuhan, China. 3. Brain Research Institute, Taihe Hospital, Shiyan, China.
Abstract
BACKGROUND: Triple-negative breast cancer (TNBC) is a subtype of invasive breast cancer that tests negative for PR, ER and excess HER2 protein. TNBC has a greater progression potential with poorer prognosis, compared with other types of breast cancer. Endothelial cell-specific molecule 1 (ESM1), also known as endocan, is overexpressed in various cancers including breast cancer and may play an important role in cancer progression. METHODS: The online resource of The Cancer Genome Atlas (TCGA) was used for analyzing the expression alteration of ESM1 in breast cancer patient tissues. We examined the changes of various malignant behaviors of TNBC cell and in vivo tumor growth after inhibiting or overexpressing ESM1 in two human TNBC cell lines, MDA-MB-468 and MDA-MB-231. When ESM1 was knocked down or overexpressed in TNBC cell, AKT and p65 phosphorylation and Cyclin D1 expression were analyzed by western blotting. The ESM1-overexpressing TNBC cell was treated with MK-2206 and BAY-117082 at various concentrations. RESULTS: Our analyses show that ESM1 is overexpressed in TNBC cell lines as well as patient tissues, which is correlated to poor prognosis. Our results demonstrate that ESM1 knockdown decreases while overexpression of ESM1 increases in vitro proliferation, migration and invasion of TNBC cell and knockdown of ESM1 inhibits in vivo TNBC tumor growth. Our mechanistic study further discloses that ESM1 promotes the proliferation of TNBC cell through activating an Akt-dependent NF-κB/Cyclin D1 pathway. CONCLUSIONS: Our results demonstrate that ESM1 knockdown decreases while overexpression of ESM1 increases in vitro migration, proliferation and invasion of TNBC cell and knockdown of ESM1 inhibits in vivo tumor growth of TNBC in the xenograft mouse model. Our mechanistic study further discloses that ESM1 promotes the proliferation of TNBC cell through activating the Akt-dependent NF-κB/CyclinD1 pathway. Our findings expand the knowledge about the molecular mechanisms underlying TNBC progression and provide rationale for using ESM1 as a therapeutic target or prognostic marker for TNBC. 2021 Annals of Translational Medicine. All rights reserved.
BACKGROUND: Triple-negative breast cancer (TNBC) is a subtype of invasive breast cancer that tests negative for PR, ER and excess HER2 protein. TNBC has a greater progression potential with poorer prognosis, compared with other types of breast cancer. Endothelial cell-specific molecule 1 (ESM1), also known as endocan, is overexpressed in various cancers including breast cancer and may play an important role in cancer progression. METHODS: The online resource of The Cancer Genome Atlas (TCGA) was used for analyzing the expression alteration of ESM1 in breast cancer patient tissues. We examined the changes of various malignant behaviors of TNBC cell and in vivo tumor growth after inhibiting or overexpressing ESM1 in two human TNBC cell lines, MDA-MB-468 and MDA-MB-231. When ESM1 was knocked down or overexpressed in TNBC cell, AKT and p65 phosphorylation and Cyclin D1 expression were analyzed by western blotting. The ESM1-overexpressing TNBC cell was treated with MK-2206 and BAY-117082 at various concentrations. RESULTS: Our analyses show that ESM1 is overexpressed in TNBC cell lines as well as patient tissues, which is correlated to poor prognosis. Our results demonstrate that ESM1 knockdown decreases while overexpression of ESM1 increases in vitro proliferation, migration and invasion of TNBC cell and knockdown of ESM1 inhibits in vivo TNBC tumor growth. Our mechanistic study further discloses that ESM1 promotes the proliferation of TNBC cell through activating an Akt-dependent NF-κB/Cyclin D1 pathway. CONCLUSIONS: Our results demonstrate that ESM1 knockdown decreases while overexpression of ESM1 increases in vitro migration, proliferation and invasion of TNBC cell and knockdown of ESM1 inhibits in vivo tumor growth of TNBC in the xenograft mouse model. Our mechanistic study further discloses that ESM1 promotes the proliferation of TNBC cell through activating the Akt-dependent NF-κB/CyclinD1 pathway. Our findings expand the knowledge about the molecular mechanisms underlying TNBC progression and provide rationale for using ESM1 as a therapeutic target or prognostic marker for TNBC. 2021 Annals of Translational Medicine. All rights reserved.
Entities:
Keywords:
Endothelial cell-specific molecule 1 (ESM1); NF-κB; cyclin D1; proliferation; triple-negative breast cancer (TNBC)
Authors: Peng Guo; Jing Huang; Liya Wang; Di Jia; Jiang Yang; Deborah A Dillon; David Zurakowski; Hui Mao; Marsha A Moses; Debra T Auguste Journal: Proc Natl Acad Sci U S A Date: 2014-09-29 Impact factor: 11.205
Authors: Petra den Hollander; Kathryn Rawls; Anna Tsimelzon; Jonathan Shepherd; Abhijit Mazumdar; Jamal Hill; Suzanne A W Fuqua; Jenny C Chang; C Kent Osborne; Susan G Hilsenbeck; Gordon B Mills; Powel H Brown Journal: Cancer Res Date: 2016-02-26 Impact factor: 12.701
Authors: Yun Hee Kang; Na Young Ji; Seung Ro Han; Chung Il Lee; Jae Wha Kim; Young Il Yeom; Young Ho Kim; Ho Kyung Chun; Jong Wan Kim; Jin Woong Chung; Dong Kuk Ahn; Hee Gu Lee; Eun Young Song Journal: Cell Signal Date: 2012-06-23 Impact factor: 4.315
Authors: Hana Jin; Trojan Rugira; Young Shin Ko; Sang Won Park; Seung Pil Yun; Hye Jung Kim Journal: Cancers (Basel) Date: 2020-05-26 Impact factor: 6.639